COMPARE · Reviewed July 29, 2026
ALNY vs AUPH
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 74.0, AUPH scored 78.9 — AUPH leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
74
$286.62 · $38.3B
fundamentals as of
Score gap
4.9
AUPH leads
AUPH
Aurinia Pharmaceuticals Inc.
78.9
$15.18 · $2.0B
fundamentals as of
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
AUPH
64
Qualityreturns · margins · balance sheet
81
100
Growthrevenue & earnings expansion
67
63
Valuevaluation vs sector peers
91
AUPH is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
AUPH
$465mC
FCF
$167mC
+65.2%A
Rev
+20.6%A-
2.76D
D/E
0.12B+
72.0xC
P/E
7.0xA
0.49A
PEG
0.34A
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
AUPH
250% above
Price vs fair valuelower is cheaper
21% below
~49%/yr
Growth the price implies10-yr FCF · lower = less priced in
~4%/yr
-78%
1-yr DCF upside
+7%
-71%
5-yr DCF upside
+26%
-57%
10-yr DCF upside
+59%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
AUPH
Why this score
- Buying back stock
- Earnings outpace cash
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $38.3b. Down 42% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 23 sell-side analysts rate this a Buy with a mean 1-yr target of $432.04 (implying +51% upside).
Moat
ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 167% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.76 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trailing P/E 72.0x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.0b. Down 21% from 52-week high of $19.25 — deep drawdown territory. Revenue growing +21%, comfortably above the S&P median. PEG 0.34 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +12% upside).
Moat
Net margin 100% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 53% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.42 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.